Key points are not available for this paper at this time.
Cefiderocol, a new siderophore cephalosporin, has been approved in the United States and Europe but not in China. At present, there are almost no antimicrobial susceptibility evaluation data on cefiderocol in China.
Wang et al. (2022) studied this question.